Новые перспективы междисциплинарного применения метформина в клинической практике врача: роль в лечении неалкогольной жировой болезни печени

На сегодняшний день, несмотря на внедрение методов первичной и вторичной профилактики, хронические неинфекционные заболевания остаются основной причиной высокой заболеваемости и смертности во всем мире. В настоящее время НАЖБП приобретает особое значение в связи с высокой распространенностью, особенно у лиц с метаболическим синдромом и развитием кардиоваскулярных заболеваний и их осложнений. Одним из перспективных направлений лечения НАЖБП является терапия инсулиносенситайзерами, к которым относится метформин. Настоящий обзор посвящен эпидемиологии, патофизиологии НАЖБП и СД 2 типа, а также механизмам действия метформина и его влиянию на некоторые процессы, лежащие в основе развития и взаимосвязи этих заболеваний.

1. Roglic, Gojka. WHO Global report on diabetes: A summary. International Journal of Noncommunicable Diseases 1(1): p 3–8, Apr–Jun 2016. | DOI: 10.4103/2468-8827.184853.

2. Алгоритмы специализированной медицинской помощи больным сахарным диабетом / Под редакцией И. И. Дедова, М. В. Шестаковой, А. Ю. Майорова. – 11-й выпуск. – М.; 2023. doi: https://doi.org/10.14341/DM13042.

3. International Diabetes Federation. IDF Diabetes Atlas. Ninth edition. 2019. URL: https://www.diabetesatlas.org/upload/resources/2019/IDF_Atlas_9th_Edition_2019.pdf (дата обращения – 15.01.2020).

4. Bhat A, Sebastiani G, Bhat M. Systematic review: preventive and therapeutic applications of metformin in liver disease. World J Hepatol. (2015) 7:1652–9. 10.4254/wjh.v7.i12.1652.

5. Portillo-Sanchez P, Bril F, Maximos M, Lomonaco R, Biernacki D, Orsak B, Subbarayan S, Webb A, Hecht J, Cusi K. High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. J Clin Endocrinol Metab 2015; 100:2231–2238.

6. Hydes TJ, Summers N, Brown E, Alam U, Thomaides-Brears H, Wilding JPH, Cuthbertson DJ. Mechanisms, screening modalities and treatment options for individuals with non-alcoholic fatty liver disease and type 2 diabetes. Diabet Med. 2020 Nov;37(11):1793–1806. doi: 10.1111/dme.14356. Epub 2020 Jul 13.

7. Stynen B, Abd-Rabbo D, Kowarzyk J, Miller-Fleming L, Aulakh SK, Garneau P, et al. Changes of cell biochemical states are revealed in protein homomeric complex dynamics. Cell. (2018) 175:1418–29. 10.1016/j.cell.2018.09.050.

8. Nassir F. NAFLD: Mechanisms, Treatments, and Biomarkers. Biomolecules. 2022 Jun 13;12(6):824. doi: 10.3390/biom12060824.

9. Day CP, James OF. Steatohepatitis: a tale of two “hits”? Gastroenterology. 1998 Apr;114(4):842–5. doi: 10.1016/s0016-5085(98)70599-2.

10. Sharma M, Mitnala S, Vishnubhotla RK, Mukherjee R, Reddy DN, Rao PN. The Riddle of Nonalcoholic Fatty Liver Disease: Progression From Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis. J Clin Exp Hepatol. 2015 Jun;5(2):147–58. doi: 10.1016/j.jceh.2015.02.002. Epub 2015 Feb 16.

11. Tanase D.M., Gosav E. M., Costea C. F., Ciocoiu M., Lacatusu C. M., Maranduca M. A., Ouatu A., Floria M. The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD) J. Diabetes Res. 2020;2020:3920196. doi: 10.1155/2020/3920196.

12. Lana A, Valdés-Bécares A, Buño A, et al. Serum leptin concentration is associated with incident frailty in older adults. Aging and Disease. 2017;8(2):240. doi: 10.14336/AD.2016.0819.

13. Morales DR, Morris AD. Metformin in cancer treatment and prevention. Annu Rev Med. (2015) 66:17–29. 10.1146/annurev-med-062613–093128.

14. Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016 Aug;65(8):1038–48. doi: 10.1016/j.metabol.2015.12.012. Epub 2016 Jan 4.

15. Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023 Apr 1;77(4):1335–1347. doi: 10.1097/HEP.0000000000000004.

16. Fouad Y, Waked I, Bollipo S, Gomaa A, Ajlouni Y, Attia D. What’s in a name? Renaming ‘NAFLD’ to ‘MAFLD’. Liver Int. 2020 Jun;40(6):1254–1261. doi: 10.1111/liv.14478. Epub 2020 Apr 28.

17. Lee CH, Lui DT, Lam KS. Non-alcoholic fatty liver disease and type 2 diabetes: An update. J Diabetes Investig. 2022 Jun;13(6):930–940. doi: 10.1111/jdi.13756.

18. Pouwels S, Sakran N, Graham Y, Leal A, Pintar T, Yang W, Kassir R, Singhal R, Mahawar K, Ramnarain D. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord. 2022 Mar 14;22(1):63. doi: 10.1186/s12902-022-00980-1.

19. Grander C, Grabherr F, Tilg H. Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options. Cardiovasc Res. 2023 Aug 7;119(9):1787–1798. doi: 10.1093/cvr/cvad095.

20. Lana A, Valdés-Bécares A, Buño A, et al. Serum leptin concentration is associated with incident frailty in older adults. Aging and Disease. 2017;8(2):240. doi: 10.14336/AD.2016.0819.

21. Guo X, Yin X, Liu Z, Wang J. Non-Alcoholic Fatty Liver Disease (NAFLD) Pathogenesis and Natural Products for Prevention and Treatment. Int J Mol Sci. 2022 Dec 7;23(24):15489. doi: 10.3390/ijms232415489.

22. Lumba R., Securiton V., Lee V., Long T., Klitgord N., Bhatt A., Delai P. S., Cassi K., Betancourt R., Highlander S. K., etc. A metagenomic signature based on the gut microbiome for noninvasive detection of advanced fibrosis in non-alcoholic fatty liver disease in humans. Metabo of cells. 2017;25:1054–1062.e1055. doi: 10.1016/j.cmet.2017.04.001.

23. Pryor R, Martinez-Martinez D, Quintaneiro L, Cabreiro F. The Role of the Microbiome in Drug Response. Annu Rev Pharmacol Toxicol. 2020 Jan 6;60:417–435. doi: 10.1146/annurev-pharmtox-010919-023612. Epub 2019 Aug 6.

24. de Faria Ghetti F, et al. Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis. Eur J Nutr. 2018;57(3):861–876.

25. Wijarnpreecha, Karn А.et al. Small intestinal bacterial overgrowth and nonalcoholic fatty liver disease: a systematic review and meta-analysis European Journal of Gastroenterology & Hepatology: May 2020 – Volume 32 – Issue 5 – p 601–608 doi: 10.1097/MEG.0000000000001541.

26. Roehlen N, Crouchet E, Baumert TF. Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives. Cells. 2020 Apr 3;9(4):875. doi: 10.3390/cells9040875.

27. Seliverstov PV, et al. Saccharomyces boulardii modulates the composition of the gut microbiota in patients with non-alcoholic fatty liver disease, thus preventing the progression of the disease. Eksp Klin Gastroenterol. 2018;(2):4–18.

28. Raman M, Ahmed I, Gillevet PM, Probert CS, Ratcliffe NM, Smith S, Greenwood R, Sikaroodi M, Lam V, Crotty P, Bailey J, Myers RP, Rioux KP. Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2013;11:868–875. e1–3.

29. Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F et al; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Ann Hepatol. 2023 Jun 24;29(1):101133. doi: 10.1016/j.aohep.2023.101133. Epub ahead of print.

30. Van Steen M. F., de Graaf A. A., Green A. K. The effect of metformin and statins on lipid and glucose metabolism and the possible benefits of combination therapy. Cardiovask. Diabetol.2018; 17:94. doi: 10.1186/s12933-018-0738-4.

31. Al-Agrudi N.N., Kurzbach A., Rodionov R. N., O’Sullivan J., Roden M., Birkenfeld A. L., Pasta D. H. Is lifestyle therapy effective for the treatment of NAFLD? Trends Endocrinologist. Metab.2019; 30:701–709. doi: 10.1016/j.tem.2019.07.013.

32. Marshall SM. 60 years of metformin use: a glance at the past and a look to the future. Diabetologia. 2017 Sep;60(9):1561–1565. doi: 10.1007/s00125-017- 4343-y. PMID: 28776085de Faria Ghetti F, et al. Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis. Eur J Nutr. 2018;57(3):861–876.

33. Karlsson C. L., Onnerfält J., Xu J., Molin G., Ahrné S, Thorngren-Jerneck K. The microbiota of the gut in preschool children with normal and excessive body weight // Obesity (Silver Spring). 2012; 20: 2257–2261.

34. Everard A., Belzer C., Geurts L., Ouwerkerk J. P., Druart C., Bindels L. B., Guiot Y., Derrien M., Muccioli G. G., Delzenne N. M. et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity // Proc Natl Acad Sci USA. 2013; 110: 9066–9071.

35. Shin N. R., Lee J. C., Lee H. Y., Kim M. S., Whon T. W., Lee M. S., Bae J. W. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice // Gut. 2014; 63: 727–735.

36. Hu H, Wang J, Li X, Shen L, Shi D, Meng J. The Effect of Metformin on Aminotransferase Levels, Metabolic Parameters and Body Mass Index in Nonalcoholic Fatty Liver Disease Patients: A Metaanalysis. Curr Pharm Des. 2021;27(29):3235– 3243. doi: 10.2174/1381612827666210315144821.

37. Donadon V, Balbi M, Mas MD, Casarin P, Zanette G (2010) Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int 30: 750–758.

38. Huang Y, Wang X, Yan C, Li C, Zhang L, Zhang L, Liang E, Liu T, Mao J. Effect of metformin on nonalcoholic fatty liver based on meta-analysis and network pharmacology. Medicine (Baltimore). 2022 Oct 28;101(43): e31437. doi: 10.1097/MD.0000000000031437. PMID: 36316840; PMCID: PMC9622616.

39. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016 Jun;64(6):1388–402. doi: 10.1016/j.jhep.2015.11.004. Epub 2016 Apr 7.

40. Ивашкин В.Т., Маевская М. В., Жаркова М. С., Котовская Ю. В., Ткачева О. Н., Трошина Е. А. и др. Клинические рекомендации Российского общества по изучению печени, Российской гастроэнтерологической ассоциации, Российской ассоциации эндокринологов, Российской ассоциации геронтологов и гериатров и Национального общества профилактической кардиологии по диагностике и лечению неалкогольной жировой болезни печени. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2022;32(4):104–140. https://doi.org/10.22416/1382–4376–2022–32–4–104–140.